BioNexus Gene Lab Corp (BGLC)
NASDAQ:BGLC
BGLC Stock Chart & Stats
$2.20
-$0.02(-6.05%)
At close: 4:00 PM EST
$2.20
-$0.02(-6.05%)
Day’s Range― - ―
52-Week Range$1.07 - $15.60
Previous Close$0.33
Volume739.27K
Average Volume (3M)128.33K
Market Cap
$5.10M
Enterprise Value$918.42K
Total Cash (Recent Filing)$3.96M
Total Debt (Recent Filing)$216.43K
Price to Earnings (P/E)―
Beta0.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding2,417,314
10 Day Avg. Volume30,313
30 Day Avg. Volume128,333
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.85
Price to Sales (P/S)0.99
P/FCF Ratio-3.91
Enterprise Value/Market Cap0.18
Enterprise Value/Revenue0.17
Enterprise Value/Gross Profit1.28
Enterprise Value/Ebitda-0.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioNexus Gene Lab Corp News
BGLC FAQ
What was BioNexus Gene Lab Corp’s price range in the past 12 months?
BioNexus Gene Lab Corp lowest stock price was $1.07 and its highest was $15.60 in the past 12 months.
What is BioNexus Gene Lab Corp’s market cap?
BioNexus Gene Lab Corp’s market cap is $5.10M.
When is BioNexus Gene Lab Corp’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BioNexus Gene Lab Corp’s earnings last quarter?
Currently, no data Available
Is BioNexus Gene Lab Corp overvalued?
According to Wall Street analysts BioNexus Gene Lab Corp’s price is currently Overvalued.
Does BioNexus Gene Lab Corp pay dividends?
BioNexus Gene Lab Corp does not currently pay dividends.
What is BioNexus Gene Lab Corp’s EPS estimate?
BioNexus Gene Lab Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioNexus Gene Lab Corp have?
BioNexus Gene Lab Corp has 2,417,314 shares outstanding.
What happened to BioNexus Gene Lab Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioNexus Gene Lab Corp?
Currently, no hedge funds are holding shares in BGLC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioNexus Gene Lab Corp
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
Technical Analysis
Ownership Overview
―
Insiders
0.10% Mutual Funds
1.98% Other Institutional Investors
97.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---